Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis

The Journal of Pediatrics
G M NixonK Grimwood

Abstract

To determine the clinical consequences of acquiring Pseudomonas aeruginosa infection during early childhood in children with cystic fibrosis (CF). Prospective, observational cohort study of 56 children with CF identified by newborn screening during 1990-92. Each child underwent an annual bronchial lavage during the first 2 to 3 years of life. Clinical outcome was determined at 7 years of age. P aeruginosa infection was diagnosed in 24 (43%) cohort subjects. Four children died before 7 years of age, all of whom had been infected with a multi-resistant, mucoid strain of P aeruginosa (P =.04). In survivors, P aeruginosa infection was associated with significantly increased morbidity as measured by lower National Institutes of Health scores, greater variability in lung function, increased time in the hospital, and higher rates of recombinant human deoxyribonuclease therapy (P <.01). In this young CF cohort, best forced expiratory volume in 1 second was an insensitive measure of increased morbidity. Acquisition of P aeruginosa was common by 7 years of age in this CF birth cohort and was associated with increased morbidity and mortality. An improved disease severity score would improve the evaluation and study of early CF lung disease.

References

Mar 1, 1992·Pediatric Pulmonology·R L HenryL Petrovic
Mar 1, 1973·The Journal of Pediatrics·L M TaussigP A Di Sant'Agnese
Aug 1, 1995·Journal of Clinical Epidemiology·C A DemkoP B Davis
Jun 17, 1995·BMJ : British Medical Journal·D S ArmstrongP D Phelan
Jan 1, 1993·The Journal of Pediatrics·S C FitzSimmons
Nov 14, 1997·American Journal of Respiratory and Critical Care Medicine·D S ArmstrongP D Phelan
Jan 15, 1999·Pediatric Pulmonology·D ArmstrongP D Phelan
Jul 29, 2000·The Medical Journal of Australia·R J MassieI Francis

❮ Previous
Next ❯

Citations

Mar 14, 2007·Epidemiology and Infection·I J CliftonS P Conway
Jan 14, 2010·European Journal of Human Genetics : EJHG·Kathryn E McDougalGarry R Cutting
Mar 22, 2007·Proceedings. Biological Sciences·Freya Harrison, Angus Buckling
Jul 17, 2009·Proceedings. Biological Sciences·Rolf KümmerliFreya Harrison
Jan 15, 2011·Clinical Microbiology Reviews·Alan R HauserSusanna A McColley
Apr 9, 2010·Clinical Microbiology Reviews·John J Lipuma
Jan 17, 2004·Clinical Microbiology Reviews·Lisa Saiman, Jane Siegel
Mar 6, 2009·Journal of Clinical Microbiology·Timothy J KiddUNKNOWN ACPinCF Investigators
Sep 24, 2002·Archives of Disease in Childhood·G M NixonClaire Wainwright
Mar 28, 2007·Thorax·Christopher H Goss, Jane L Burns
Jul 2, 2002·American Journal of Respiratory and Critical Care Medicine·Paulo J C MarosticaRobert S Tepper
Oct 3, 2002·American Journal of Respiratory and Critical Care Medicine·David S ArmstrongKeith Grimwood
Dec 14, 2002·American Journal of Respiratory and Critical Care Medicine·Ronald L GibsonUNKNOWN Cystic Fibrosis Therapeutics Development Network Study Group
Aug 15, 2003·American Journal of Respiratory and Critical Care Medicine·Philip M FarrellMark L Splaingard
Oct 14, 2003·American Journal of Respiratory and Critical Care Medicine·Ronald L GibsonBonnie W Ramsey
Dec 14, 2004·American Journal of Respiratory and Critical Care Medicine·David M RodmanJerry A Nick
Nov 16, 2004·American Journal of Respiratory and Critical Care Medicine·Andrew M JonesA Kevin Webb
Nov 9, 2004·American Journal of Respiratory and Critical Care Medicine·Richard KraemerSabina Gallati
Feb 15, 2005·American Journal of Respiratory and Critical Care Medicine·Amanda L GriffithsDavid S Armstrong
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·David E GellerUNKNOWN Mpex 204 Study Group
Feb 19, 2011·American Journal of Respiratory and Critical Care Medicine·Malena Cohen-CymberknohEitan Kerem
Oct 3, 2002·American Journal of Respiratory and Critical Care Medicine·David P SpeertEshwar Mahenthiralingam
Apr 19, 2005·American Journal of Respiratory Cell and Molecular Biology·Deborah A LewisEshwar Mahenthiralingam
Apr 15, 2006·American Journal of Respiratory Cell and Molecular Biology·Jerry M WrightMichael P Boyle
Nov 9, 2010·BMC Pulmonary Medicine·Amy J Scott-ThomasStephen T Chambers
Jan 22, 2011·BMC Pulmonary Medicine·Becky A BriesacherLynne M Quittell
Dec 17, 2004·Annals of Clinical Microbiology and Antimicrobials·Terence E McManusStuart J Elborn
Jul 20, 2010·Annals of Clinical Microbiology and Antimicrobials·Heidi L WilliamsCynthia B Whitchurch
Dec 8, 2009·Chest·Justin R OrtizChristopher H Goss
Jul 27, 2007·Proceedings of the American Thoracic Society·Nicole Mayer-HamblettRichard A Kronmal
Jul 27, 2007·Proceedings of the American Thoracic Society·Stephanie D DavisMargaret Rosenfeld
Feb 12, 2002·Pharmacotherapy·Allyson S Gaylor, Joan C Reilly
Mar 20, 2002·Pharmacotherapy·Patrick Flume, Michael E Klepser
Apr 24, 2013·Annals of the American Thoracic Society·Sarath C RanganathanUNKNOWN Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF) *
May 27, 2014·Therapeutic Delivery·Misagh Alipour, Zacharias E Suntres
Jan 9, 2009·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Iain L LamontDavid W Reid
Dec 8, 2015·Applied Microbiology and Biotechnology·Andreia P MagalhãesSusana P Lopes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.